

INFORMATION DISCLOSURE STATEMENT

Applicant : Weber, Eckard, et al.
App. No : 10/828,795
Filed : April 21, 2004
For : COMPOSITIONS FOR AFFECTING WEIGHT LOSS
Examiner : Kwon, Brian Yong S.
Art Unit : 1614

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 14 references to be considered by the Examiner. Also enclosed are 10 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/28/07

By: 
Brenden Gingrich
Registration No. 60,295
Attorney of Record
Customer No. 20,995
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/828,795
(Multiple sheets used when necessary)		Filing Date	April 21, 2004
		First Named Inventor	Weber, Eckard
		Art Unit	1614
SHEET 1 OF 1		Examiner	Kwon, Brian Yong S.
		Attorney Docket No.	OREX.001A

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,387,956	05-14-2002	Shapira	
	2	2003-0055038	03-20-2003	Howard	
	3	2003-0130322	07-10-2003	Howard	
	4	2004-0158194	08-12-2004	Wolff, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	5	WO 94/20100	09-15-1994	Nagle et al.		
	6	WO 03/097046 A1	11-27-2003	Duke University		
	7	WO 2004/024096 A2	03-25-2004	Elan pharma		
	8	WO 2004/100992 A2	11-25-2004	Pfizer		
	9	WO 2004/050020 A2	06-17-2004	Simon, David L.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	10	Croft et al., "Effect on body weight of buropion sustained-release in patients with major depression treated for 52 weeks," Clinical Therapeutics 24(4):662-672 (Apr. 2002)	
	11	McDougle, et al., "A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder," Archive of General Psychiatry, 57(8):794-801 August 2000	
	12	Nash et al., "Anxiety disorders," Medicine, 32(7):17-21, July 1, 2004	
	13	Stein, "Neurobiology of the obsessive-compulsive spectrum disorders," Biological Psychiatry 47(4):296-304 February 15, 2000	
	14	Stein, "Obsessive-compulsive disorder," Lancet 360(9330):397-405 August 3, 2002	

3945377
062907

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.